The global celiac disease market is predicted to grow at a CAGR of 8.5% during the forecast period.
The increasing therapeutic product penetration in emerging economies, rising diabetes cases, increasing the number of clinical trials for drugs against celiac disease, and increasing gluten consumption, which leads to celiac disease, are the major factors for market expansion. For instance, according to the Center for Disease Control and Prevention, in 2020, there were around 34.2 million people have diabetes in the US which is 10.5% of the US population.
Furthermore, rising technical developments and expanding modernization in the healthcare sector, as well as rising research and development activities, would generate new chances for the celiac disease treatment market during the forecasted period.
The global celiac disease market has seen a strong decline during the COVID-19 pandemic as celiac disease patients were highly at risk across the globe. Celiac disease is an autoimmune illness caused by a lack of tolerance for gluten, a protein found in or added to a variety of foods. The manufacturing industries have been halted their operations impacting the overall supply chain.
Key Topics Covered:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
3. Competitive Landscape
3.1. Key Company Analysis
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Determinants
5. Market Segmentation
5.1. Global Celiac Disease Market by Treatment Type
5.1.1. Vitamins and Dietary (Gluten-Free) Supplements
5.1.2. Steroids and Immunosuppressive Drugs
5.1.3. Therapeutic Vaccines
5.2. Global Celiac Disease Market by Diagnostic Type
5.2.1. Serologic Test
5.2.2. Genetic Testing
5.2.3. Small-Bowel Biopsy
5.3. Global Celiac Disease Market by End-User
5.3.1. Hospitals and Diagnostics Centers
5.3.2. Research Institutes
6. Regional Analysis
7. Company Profiles
7.1. Abbott Laboratories
7.2. AbbVie Inc.
7.3. ADMA Biologics, Inc.
7.4. Amgen Inc.
7.5. Bayer AG
7.6. Bio Rad Laboratories, Inc.
7.7. BioLineRX Ltd.
7.8. Boston Scientific Corp.
7.9. Bristol-Myers Squibb Co.
7.10. Calypso Biotech SA
7.11. ChemoCentryx, Inc.
7.12. Eli Lilly And Co.
7.13. GlaxoSmithKline plc
7.14. ImmunogenX, Inc.
7.15. Janssen Pharmaceuticals, Inc.
7.16. Johnson & Johnson Services Inc.
7.17. Merck & Co., Inc.
7.18. Sanofi S.A
7.19. Thermo Fisher Scientific Inc.
7.20. ZEDIRA GmbH
For more information about this report visit https://www.researchandmarkets.com/r/qij54a
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005671/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900